Gaël Krysa
Publications by Year
Research Areas
Protein Degradation and Inhibitors, Multiple Myeloma Research and Treatments, Cancer Immunotherapy and Biomarkers, Cancer, Hypoxia, and Metabolism, RNA Interference and Gene Delivery
Most-Cited Works
- → Identification of 1,5-Naphthyridine Derivatives as a Novel Series of Potent and Selective TGF-β Type I Receptor Inhibitors(2004)219 cited
- → Identification of a novel series of BET family bromodomain inhibitors: Binding mode and profile of I-BET151 (GSK1210151A)(2012)207 cited
- → The Discovery of I-BET726 (GSK1324726A), a Potent Tetrahydroquinoline ApoA1 Up-Regulator and Selective BET Bromodomain Inhibitor(2014)187 cited
- → Inhibition of TGF‐β signaling by an ALK5 inhibitor protects rats from dimethylnitrosamine‐induced liver fibrosis(2005)164 cited
- → From ApoA1 upregulation to BET family bromodomain inhibition: Discovery of I-BET151(2012)118 cited
- → Design of novel quinazoline derivatives and related analogues as potent and selective ALK5 inhibitors(2009)81 cited
- → Naphthyridines as Novel BET Family Bromodomain Inhibitors(2013)34 cited
- → A Potent and Selective Kallikrein-5 Inhibitor Delivers High Pharmacological Activity in Skin from Patients with Netherton Syndrome(2021)32 cited
- → Abstract 3228: Immune checkpoint blockade and autoimmune diseases: Development of a mouse model of colitis induced by anti-CTLA-4(2019)2 cited
- → Abstract 1654: Mouse models of hepatocellular carcinoma: A comprehensive and functional preclinical platform for immunotherapy research(2022)